Pacific Edge - Latest News [Page 1]

Pacific Edge Reports Continued Strong Revenue Growth Despite Ongoing Impact Of Covid-19

Thursday, 25 November 2021, 8:59 am | Pacific Edge

Cancer diagnostics business, Pacific Edge Limited (NZX/ASX: PEB) has reported continuing growth for the six months ended 30 September 2021 (1H22), with key performance metrics significantly ahead of the same time last year, driven by reimbursement milestones, ... More >>

Pacific Edge Announces Appointment Of New CEO

Friday, 29 October 2021, 9:37 am | Pacific Edge

Cancer diagnostics company Pacific Edge (NZX: PEB, ASX: PEB) today announces the appointment of Dr Peter Meintjes, an experienced molecular diagnostics and genomics business leader, as its new Chief Executive Officer. Dr Meintjes, a New Zealand citizen ... More >>

Pacific Edge Financial Results For The 12 Months To 31 March 2021

Thursday, 27 May 2021, 9:32 am | Pacific Edge

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to report accelerating revenue growth in its key markets as it starts to benefit from the major commercial milestones achieved in FY21 and despite the ongoing challenges and headwinds ... More >>

Pacific Edge CEO, David Darling, Announces Intention To Retire

Monday, 12 April 2021, 9:59 am | Pacific Edge

Pacific Edge Limited (NZX: PEB) announces that CEO, David Darling, has advised the company’s Board that he intends to retire from his role on 6 April 2022. Following this, David will continue to support the company in a consulting role. The Board ... More >>

Commercial Evaluation Confirms Clinical Outperformance Of Cxbladder

Monday, 21 December 2020, 10:09 am | Pacific Edge

Peer reviewed publication of further independent, real-world clinical evidence highlights the effectiveness, safety and long term clinical utility from inclusion of Cxbladder in a new standard of care in mainstream clinical use. Cancer diagnostics company, ... More >>

Pacific Edge Appoints David Levison To USA Executive Team To Drive USA Growth

Thursday, 19 November 2020, 10:15 am | Pacific Edge

New Zealand cancer diagnostics company Pacific Edge Limited (NZX: PEB) today announces a new leadership structure to strengthen the executive team of its US based subsidiary, Pacific Edge Diagnostics USA Limited (PEDUSA). Coupled with this Pacific Edge is ... More >>

Pacific Edge Deemed An Essential Provider

Wednesday, 25 March 2020, 11:21 am | Pacific Edge

Cancer diagnostic company, Pacific Edge, advises that its medical and diagnostic services laboratories in both New Zealand and the USA have been identified as Essential Businesses and that they are operating during the Government-directed COVID-19 shutdowns. ... More >>

Significant achievement with Cxbladder added to guidelines

Monday, 15 July 2019, 2:21 pm | Pacific Edge

Cancer diagnostics company, Pacific Edge (NZX: PEB), advises that Cxbladder has been included in the latest version of the National Comprehensive Cancer Network (NCCN) Guidelines for Bladder Cancer in the USA. More >>

Pacific Edge Reports Continued Growth in FY19

Wednesday, 29 May 2019, 9:53 am | Pacific Edge

Cancer diagnostics company, Pacific Edge (NZX: PEB) has today released its audited financial results for the year ended 31 March 2019, reporting accelerating demand from new and existing customers in the second half of the financial year, particularly ... More >>

Further Compelling Clinical Evidence Supporting Cxbladder

Friday, 17 May 2019, 2:27 pm | Pacific Edge

• Cxbladder providing enhanced diagnostic outcomes not currently available from existing technology. • Enables physicians to remove the diagnostic dilemma faced, when existing gold standard tests and procedures are not able to determine a clear ... More >>

Full Suite of Cxbladder Tests Adopted by DHB

Thursday, 8 November 2018, 1:32 pm | Pacific Edge

Full Suite of Cxbladder Tests Adopted by New Zealand Public Healthcare Provider Capital & Coast Dhb Pacific Edge signs agreement with Capital & Coast District Health Board, providing access to full suite of Cxbladder products Cancer diagnostics company, ... More >>

Pacific Edge preliminary financial results for FY18

Tuesday, 29 May 2018, 1:20 pm | Pacific Edge

Listed cancer diagnostics company, Pacific Edge Limited (NZX: PEB), has today announced its preliminary unaudited full year results for the year ended 31 March 2018, reporting increased test numbers and revenues as more urologists and healthcare organisations ... More >>

Pacific Edge Signs First Commercial Agreement in Singapore

Thursday, 1 February 2018, 1:50 pm | Pacific Edge

Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has reached a commercial agreement with Raffles Diagnostica Pte Ltd to offer its suite of Cxbladder tests in Singapore. More >>

Pacific Edge Financial Year 18 - Interim Results

Wednesday, 29 November 2017, 9:50 am | Pacific Edge

Reported loss of $8.9m for the six months, a reduction of 23% on the loss in 1H17 More >>

Pacific Edge Named 20th in Deloitte Fast50

Friday, 10 November 2017, 10:45 am | Pacific Edge

The team at Dunedin cancer diagnostics company, Pacific Edge, is celebrating today after being named the 20th fastest growing company in the Deloitte Fast50 Awards, coming in with 324% growth in revenue over three years, and is the only healthcare ... More >>

Pacific Edge Named #6 in TIN Top Ten Hot Emerging Companies

Wednesday, 18 October 2017, 10:01 am | Pacific Edge

Pacific Edge’s global growth and positive revenue trajectory has been recognised with the cancer diagnostics company named number 6 in the TIN Top Ten List of Hot Emerging Companies for 2017. More >>

Pacific Edge 2017 Annual Meeting

Friday, 25 August 2017, 11:09 am | Pacific Edge

Pacific Edge held its Annual Meeting in Dunedin on 24 August 2017, updating shareholders on its strategic progress, particularly in the US which is the company’s primary opportunity. A positive and supportive group of shareholders attended both in Dunedin ... More >>

Pacific Edge Cxbladder Test Suite Adopted by Midcentral DHB

Thursday, 3 August 2017, 10:25 am | Pacific Edge

Pacific Edge Signs Agreement Extending Commercial Partnership with MidCentral District Health Board, to Encompass All Cxbladder Tests for Application Across the Clinical Pathway More >>

Pacific Edge Limited Full Year Results to 31 March 2017

Wednesday, 24 May 2017, 10:40 am | Pacific Edge

Steady growth in sales and laboratory throughput; strong progress on targeted transformational customers • Total revenue up 33% to $9.5m, including a 62% increase in operating revenue up to $8.1m with growth coming from new and existing commercial customers ... More >>

Callaghan Innovation Growth Grant for Pacific Edge

Tuesday, 21 March 2017, 3:19 pm | Pacific Edge

Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) is pleased to advise that it has received an additional grant of up to $3 million to its existing Growth Grant from Callaghan Innovation to enable further research and development of its ... More >>